BMO Initiates Medline Coverage with $45 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ANDG?
Source: Benzinga
- Medline Coverage Initiation: BMO Capital analyst Sean Dodge initiated coverage on Medline Inc (NASDAQ:MDLN) with an Outperform rating and a price target of $45, indicating an approximate 11% upside from the current share price of $40.52, reflecting confidence in the company's growth prospects.
- Hims & Hers Rating Update: Evercore ISI Group analyst Mark Mahaney initiated coverage on Hims & Hers Health Inc (NYSE:HIMS) with an In-Line rating and a price target of $33, suggesting a stable growth outlook as the current share price stands at $31.69.
- Andersen Group Coverage Initiation: UBS analyst Kevin Mcveigh initiated coverage on Andersen Group Inc (NYSE:ANDG) with a Buy rating and a price target of $28, indicating significant upside potential from the current price of $24.29, reflecting optimism about its market performance.
- Netflix Rating Update: HSBC analyst Mohammed Khallouf initiated coverage on Netflix Inc (NASDAQ:NFLX) with a Buy rating and a price target of $107, suggesting an approximate 19% upside from the current share price of $89.44, indicating confidence in its content strategy and market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANDG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANDG
Wall Street analysts forecast ANDG stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 23.940
Low
22.00
Averages
30.00
High
40.00
Current: 23.940
Low
22.00
Averages
30.00
High
40.00
No data
About ANDG
Andersen Group Inc. is a provider of independent tax, valuation and financial advisory services to individuals and family offices, businesses and institutional clients in the United States. The Company’s primary end-to-end services offerings include private client services, business tax services, alternative investment funds, and valuation services. Its private client services include comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving and trust and estate plan. Its business tax services offer a range of integrated tax-related consulting and compliance services for businesses, helping organizations with managing their tax planning, compliance and reporting needs effectively. Its alternative investment funds deliver comprehensive tax and financial services for a range of investment funds including family offices, funds of funds, hedge funds, and private equity funds.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Andersen Group to Announce 2025 Financial Results
- Earnings Announcement Schedule: Andersen Group will announce its financial results for the full year and fourth quarter of 2025 after market close on March 17, 2026, providing crucial insights into financial performance and business metrics for investors.
- Executive Conference Call: CEO Mark L. Vorsatz and CFO Neal Livingston will host a conference call on the same day at 5 PM ET to discuss the financial results, enhancing transparency and facilitating direct communication with investors.
- Webcast Access: Participants can join the conference call via the provided webcast link, with the replay archived on Andersen's Investor Relations website for easy access by investors who cannot attend live.
- Global Business Overview: Andersen operates in over 180 countries, delivering independent tax, valuation, and financial advisory services with more than 3,000 partners and 50,000 professionals, showcasing its leadership and service capabilities in the industry.
See More
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.
Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.
See More
Three Companies Make Their Debut Today as the IPO Market Gains Momentum: SpaceX, OpenAI, and Anthropic on the Horizon.
Upcoming IPOs: Three new IPOs are set to launch today, attracting investor attention.
Key Players: The companies involved in these IPOs include SpaceX, OpenAI, and Anthropic.
Market Anticipation: Investors are particularly eager for these IPOs as they await significant developments later this year.
Investment Climate: The current market environment is buzzing with excitement over these high-profile companies entering the public market.
See More
BMO Initiates Medline Coverage with $45 Price Target
- Medline Coverage Initiation: BMO Capital analyst Sean Dodge initiated coverage on Medline Inc (NASDAQ:MDLN) with an Outperform rating and a price target of $45, indicating an approximate 11% upside from the current share price of $40.52, reflecting confidence in the company's growth prospects.
- Hims & Hers Rating Update: Evercore ISI Group analyst Mark Mahaney initiated coverage on Hims & Hers Health Inc (NYSE:HIMS) with an In-Line rating and a price target of $33, suggesting a stable growth outlook as the current share price stands at $31.69.
- Andersen Group Coverage Initiation: UBS analyst Kevin Mcveigh initiated coverage on Andersen Group Inc (NYSE:ANDG) with a Buy rating and a price target of $28, indicating significant upside potential from the current price of $24.29, reflecting optimism about its market performance.
- Netflix Rating Update: HSBC analyst Mohammed Khallouf initiated coverage on Netflix Inc (NASDAQ:NFLX) with a Buy rating and a price target of $107, suggesting an approximate 19% upside from the current share price of $89.44, indicating confidence in its content strategy and market position.
See More
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
- Drug Trial Failure: Biohaven Ltd announced that its depression drug BHV-7000 failed to significantly reduce depressive symptoms in a six-week clinical trial, causing shares to plummet 14.3% to $9.27 in pre-market trading, reflecting a substantial decline in market confidence regarding its R&D capabilities.
- Severe Market Reaction: The news of the trial's failure triggered panic among investors, leading to a rapid decline in Biohaven's stock price during pre-market trading, indicating the high sensitivity of the biopharmaceutical sector to clinical outcomes, which may impact the company's future financing and R&D plans.
- Increased Competitive Pressure: With Biohaven's drug trial failure, market attention shifts to other competitors, particularly in the depression treatment space, potentially leading investors to reassess the market outlook and investment value of related companies.
- Wider Industry Implications: Biohaven's failure could have a ripple effect across the biopharmaceutical industry, particularly in terms of R&D investments and clinical trial designs, prompting other companies to more cautiously evaluate their drug development strategies.
See More
Medline Raises $6.2 Billion in Largest IPO Since 2021
- IPO Market Recovery: The US IPO market continues its gradual recovery in 2025, achieving a four-year high in both deal count and proceeds despite challenges from tariff chaos in April and a government shutdown in October, indicating resilience and investor confidence.
- Medline Leads the Charge: Medical supplies giant Medline successfully raised $6.2 billion in its IPO this week, marking the largest IPO since 2021 and highlighting the company's strong market performance and future growth potential.
- Strong Market Performance: The IPO market ticked up 0.4% this week, outperforming the S&P 500's 0.1%, reflecting positive investor sentiment towards new listings, particularly with China-based robotaxi developer Pony AI soaring 11.3%.
- Optimistic Future Outlook: With blockbuster names like SpaceX, Anthropic, and OpenAI potentially going public in 2026, the market is buzzing with anticipation for future IPO opportunities, drawing more companies' attention to the upcoming IPO wave.
See More
Andersen Group to Announce 2025 Financial Results
- Earnings Announcement Schedule: Andersen Group will announce its financial results for the full year and fourth quarter of 2025 after market close on March 17, 2026, providing crucial insights into financial performance and business metrics for investors.
- Executive Conference Call: CEO Mark L. Vorsatz and CFO Neal Livingston will host a conference call on the same day at 5 PM ET to discuss the financial results, enhancing transparency and facilitating direct communication with investors.
- Webcast Access: Participants can join the conference call via the provided webcast link, with the replay archived on Andersen's Investor Relations website for easy access by investors who cannot attend live.
- Global Business Overview: Andersen operates in over 180 countries, delivering independent tax, valuation, and financial advisory services with more than 3,000 partners and 50,000 professionals, showcasing its leadership and service capabilities in the industry.
See More
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.
Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.
See More
Three Companies Make Their Debut Today as the IPO Market Gains Momentum: SpaceX, OpenAI, and Anthropic on the Horizon.
Upcoming IPOs: Three new IPOs are set to launch today, attracting investor attention.
Key Players: The companies involved in these IPOs include SpaceX, OpenAI, and Anthropic.
Market Anticipation: Investors are particularly eager for these IPOs as they await significant developments later this year.
Investment Climate: The current market environment is buzzing with excitement over these high-profile companies entering the public market.
See More
BMO Initiates Medline Coverage with $45 Price Target
- Medline Coverage Initiation: BMO Capital analyst Sean Dodge initiated coverage on Medline Inc (NASDAQ:MDLN) with an Outperform rating and a price target of $45, indicating an approximate 11% upside from the current share price of $40.52, reflecting confidence in the company's growth prospects.
- Hims & Hers Rating Update: Evercore ISI Group analyst Mark Mahaney initiated coverage on Hims & Hers Health Inc (NYSE:HIMS) with an In-Line rating and a price target of $33, suggesting a stable growth outlook as the current share price stands at $31.69.
- Andersen Group Coverage Initiation: UBS analyst Kevin Mcveigh initiated coverage on Andersen Group Inc (NYSE:ANDG) with a Buy rating and a price target of $28, indicating significant upside potential from the current price of $24.29, reflecting optimism about its market performance.
- Netflix Rating Update: HSBC analyst Mohammed Khallouf initiated coverage on Netflix Inc (NASDAQ:NFLX) with a Buy rating and a price target of $107, suggesting an approximate 19% upside from the current share price of $89.44, indicating confidence in its content strategy and market position.
See More
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
- Drug Trial Failure: Biohaven Ltd announced that its depression drug BHV-7000 failed to significantly reduce depressive symptoms in a six-week clinical trial, causing shares to plummet 14.3% to $9.27 in pre-market trading, reflecting a substantial decline in market confidence regarding its R&D capabilities.
- Severe Market Reaction: The news of the trial's failure triggered panic among investors, leading to a rapid decline in Biohaven's stock price during pre-market trading, indicating the high sensitivity of the biopharmaceutical sector to clinical outcomes, which may impact the company's future financing and R&D plans.
- Increased Competitive Pressure: With Biohaven's drug trial failure, market attention shifts to other competitors, particularly in the depression treatment space, potentially leading investors to reassess the market outlook and investment value of related companies.
- Wider Industry Implications: Biohaven's failure could have a ripple effect across the biopharmaceutical industry, particularly in terms of R&D investments and clinical trial designs, prompting other companies to more cautiously evaluate their drug development strategies.
See More
Medline Raises $6.2 Billion in Largest IPO Since 2021
- IPO Market Recovery: The US IPO market continues its gradual recovery in 2025, achieving a four-year high in both deal count and proceeds despite challenges from tariff chaos in April and a government shutdown in October, indicating resilience and investor confidence.
- Medline Leads the Charge: Medical supplies giant Medline successfully raised $6.2 billion in its IPO this week, marking the largest IPO since 2021 and highlighting the company's strong market performance and future growth potential.
- Strong Market Performance: The IPO market ticked up 0.4% this week, outperforming the S&P 500's 0.1%, reflecting positive investor sentiment towards new listings, particularly with China-based robotaxi developer Pony AI soaring 11.3%.
- Optimistic Future Outlook: With blockbuster names like SpaceX, Anthropic, and OpenAI potentially going public in 2026, the market is buzzing with anticipation for future IPO opportunities, drawing more companies' attention to the upcoming IPO wave.
See More
